Short-term cultures of clinical tumor material: Potential contributions to oncology research

Oncology Research

Volumn 11, Issue 3, 1999, Pages 115-124

  Baguley, Bruce C ^a   Marshall, Elaine S ^a   Finlay, Graeme J ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Apoptosis; Carboplatin; Clinical; Cytokinetics; Doubling time; Paclitaxel; Primary culture; Sensitivity testing

Indexed keywords

ANTINEOPLASTIC AGENT;

CELL CULTURE; CELL DEATH; CELL DIVISION; CULTURE TECHNIQUE; DRUG EFFECT; DRUG SCREENING; FEMALE; HUMAN; MELANOMA; METHODOLOGY; NEOPLASM; OVARY TUMOR; PATHOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; CELL DEATH; CELL DIVISION; CULTURE TECHNIQUES; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MELANOMA; NEOPLASMS; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0032617363     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (94)

1. Goldin, A.; Venditti, J. M. Progress report on the screening program at the division of cancer treatment, NCI. Cancer Treat. Rev. 7:167-176; 1980.
2. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; P.aull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigrowolff, A.; Gray-Goodrich, M.; Campbell, H.; Mayo, J.; Boyd, M. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer. Inst. 83:757-766; 1991.
3. Fry, D. W.; Kraker, A. J.; Gönners, R. C.; Elliott, W. L.; Nelson, J. M.; Showalter, H. D. H.; Leopold, W. R. Strategies for the discovery of novel tyrosine kinase inhibitors with anticancer activity. Anticancer Drug Design 9:331-351; 1994.
4. Vogt, P. K.; Reed, S. I., eds. Current topics in microbiology and immunology, 227: Cyclin dependent kinase (CDK) inhibitors, 1st ed. Berlin: Springer; 1998.
5. Wilson, G. D.; McNally, N. J.; Dische, S.; Saunders, M. L; Des Rochers, C.; Lewis, A. A.; Bennett, M. H. Measurement of cell kinetics in human tumours in vivo using bromodeoxyuridine incorporation and flow cytometry. Br. J. Cancer 58:423-431; 1988.
6. Evan, G. I.; Brown, L.; Whyte, M.; Harrington, E. Apoptosis and the cell cycle. Curr. Opin. Cell. Biol. 7:825-834; 1995.
7. Kauffmanzeh, A.; Rodriguez-Viciana, P.; Ulrich, E.; Gilbert, C.; Coffer, P.; Downward, J.; Evan, G. Suppression of C-myc-induced apoptosis by ras signalling through PI(3)K and PKB. Nature 385:544-548; 1997.
8. Wyllie, A. H. Apoptosis. Br. J. Cancer 67:205-208; 1993.
9. Kluck, R. M.; Bossy-Wetzel, E.; Green, D. R.; Newmcyer, D. D. The release of cytochrome C from mitochondria: A primary site for bcl-2 regulation of apoptosis. Science 275:1132-1136; 1997.
10. Evan, G.; Littlewood, T. A matter of life and cell death. Science 281:1317-1322; 1998.
11. Meredith, J. E.; Fazeli, B.; Schwanz, M. A. The extracellular matrix as a cell survival factor. Mol. Biol. Cell. 4:953-961; 1993.
12. Ruoslahti, E.; Reed, J. C. Anchorage dependence, integrins, and apoptosis. Cell 77:477-478; 1994.
13. Frisch, S. M.; Vuori, K.; Ruoslahti, E.; Chanhui, P. Y. Control of adhesion-dependent cell survival by focal adhesion kinase. J. Cell Biol. 134:793-799; 1996.
14. Hannigan, G. E.; Leung-Hagesteijn, C.; Fitz-Gibbon, L.; Coppolino, M. G.; Radeva, G.; Filmus, J.; Bell, J. C.; Dedhar, S. Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature 379:91-96; 1996.
15. Hamburger, A. W.; Salmon, S. E. Primary bioassay of human tumor stem cells. Science 197:461-463; 1977.
16. Courtenay, V. D.; Selby, P. J.; Smith, I. E.; Mills, J.; Peckham, M. J. Growth of human tumour cell colonies from biopsies using two soft-agar techniques. Br. J. Cancer 38:77-81; 1978.
17. Tveit, K. M.; Gundersen, S.; Hoie, J.; Pihl, A. Predictive chemosensitivity testing in malignant melanoma: Reliable methodology-ineffective drugs. Br. J. Cancer 58:734-737; 1988.
18. Brock, W. A.; Baker, F. L.; Peters, L. J. Radiosensitivity of human head and neck squamous cell carcinomas in primary culture and its potential as a predictive assay of tumor radiocurability. Int. J. Radiât. Biol. 56:751-760; 1989.
19. West, C. M. L.; Davidson, S. E.; Hendry, J. H.; Hunter, R. D. Prediction of cervical carcinoma response to radiotherapy. Lancet 338:818; 1991.
20. Von Hoff, D. D.; Kronmal, R.; Salmon, S. E.; Turner, J.; Green, J. B.; Bonorris, J. S.; Moorhead, E. L.; Hynes, H. E.; Pugh, R. E.; Belt, R. J.; Alberts, D. S. A Southwest Oncology Group study on the use of a human tumor cloning assay for predicting response iii patients with ovarian cancer. Cancer 67:20-27; 1991.
21. Hanauske, A. R.; Clark, G. M.; Von Hoff, D. D. Adenocarcinoma of unknown primary-retrospective analysis of chemosensitivity of 313 freshly explanted tumors in a tumor cloning system. Invest. New Drugs 13:43-49; 1995.
22. Weisenthal, L. M.; Lippman, M. E. Clonogenic and nonclonogenic m vitro chemosensitivity assays. Cancer Treat. Rep. 69:615-632; 1985.
23. Von Hoff, D. D. He's not going to talk about in vitro predictive assays again, is he? J. Natl. Cancer. Inst. 82:96-101; 1990.
24. Finlay, G. J. In vitro systems for anti-cancer drug screening. In: Waring, M. J.; Ponder, B. A., eds. The search for new anti-cancer drugs, 1st ed. Dordrecht: Kluwer; 1992:55-85.
25. Bjork-Eriksson, T.; West, C. M. L.; Karlsson, E.; Slevin, N. J.; Davidson, S. E.; James, R. D.; Mercke, C. The in vitro radiosensitivity of human head and neck cancers. Br. J. Cancer 77:2371-2375; 1998.
26. Von Hoff, D. D. There are no bad anticancer agents, only bad clinical trial designs-Twenty First Richard and Hinda Rosenthal Foundation Award Lecture. Clin. Cancer Res. 4:1079-1086; 1998.
27. Waldman, T.; Zhang, Y. G.; Dillehay, L.; Yu, J.; Kinzler, K.; Vogelstein, B.; Williams, J. Cell-cycle arrest versus cell death in cancer therapy. Nat. Med. 3:1034-1036; 1997.
28. Marshall, E. S.; Finlay, G. J.; Matthews, J. H. L.; Shaw, J. H. F.; Nixon, J.; Baguley, B. C. Microculture-bascd chemosensitivity testing: A feasibility study comparing freshly explanted human melanoma cells with human melanoma cell lines. J. Nail. Cancer. Inst. 84:340-345; 1992.
29. Baguley, B. C.; Marshall, E. S.; Holdaway, K. M.; Rewcastle, G. W.; Denny, W. A. Inhibition of growth of primary human tumour cell cultures by a 4-aniIinoquinazoline inhibitor of the epidermal growth factor receptor family of tyrosine kinases. Eur. J. Cancer 34:1086-1090; 1998.
30. Weisenthal, L. M.; Dill, P. L.; Kurnick, N. B.; Lippman, M. E. Comparison of dye exclusion assays with a clonogcnic assay in the determination of drug-induced cytotoxicity. Cancer Res. 43: 258-264; 1983.
31. Gazdar, A. F.; Steinbcrg, S. M.; Russell, E. K.; Linnoila, R. I.; Oie, H. K.; Ghosh, B. C; Cotelingam, J. D.; Johnson, B. E.: Minna, J. D.; Ihde, D. C. Correlation of in vitro drug-sensitivity testing results with response to chemotherapy and survival in extensive-stage small cell lung cancer: A prospective clinical trial. J. Natl. Cancer. Inst. 82:117-124; 1990.
32. Baker, F. L.; Spitzer, G.; Ajani, J. A.; Brock, W. A.; Lukcman, J.; Pathak, S.; Tomasovic, B.; Thielvoldt, D.; Williams, M.; Vines, C.; Tofilon, P. Drug and radiation sensitivity measurements of successful primary monolayer culturing of human tumour cells using cell-adhesive matrix and supplemented medium. Cancer Res. 46:1263-1274; 1986.
33. Parkins, C. S.; Steel, G. G. Growth and radiosensitivity testing of human tumour cells using the adhesive tumour cell culture system. Br. J. Cancer 62:935-941; 1990.
34. Girinsky, T.; Lubin, R.; Pignon, J. P.; Chavaudra, N.; Gazeau, J.; Dubray, B.; Cosset, J. M.; Socie, G.; Fertil, B. Predictive value of in vitro radiosensitivity parameters in head and neck cancers and cervical carcinomas: Preliminary correlations with local control and overall survival. Int. J. Radiât. Oncol. Biol. Phys. 25:3-7; 1993.
35. Tanigawa, N.; Kitaoka, A.; Yamakawa, M.; Tanisaka, K.; Kobayashi, H. In vitro chemosensitivity testing of human tumours by collagen gel droplet culture and image analysis. Anticancer Res. 16:1925-1930; 1996.
36. Kovar, J.; Stunz, L. L.; Stewart, B. C.; Kriegerbeckova, K.; Ashman, R. F.; Kemp, J. D. Direct evidence that iron deprivation induces apoptosis in murine lymphoma 38C13. Pathobiology 65: 61-68; 1997.
37. Leist, M.; Raab, B.; Maurer, S.; Rosick, U.; Brigelius-Flohe, R. Conventional cell culture media do not adequately supply cells with antioxidants and thus facilitate peroxide-induced genotoxicity. Free Radie. Biol. Med. 21:297-306; 1996.
38. Brower, M.; Carney, D. N.; Oie, H. K.; Gazdar, A. F.; Minna, J. D. Growth of cell lines and clinical specimens of human nonsmall cell lung cancer in a serum-free defined medium. Cancer Res. 46:798-806; 1986.
39. Rubin, R.; Baserga, R. Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Lab. Invest. 73:311-331; 1995.
40. Slater, A. F.; Stefan, C.; Nobel, I.; van den Dobbelsteen, D. J.; Orrenius, S. Signalling mechanisms and oxidative stress in apoptosis. Toxicol. Lett. 82-83:149-153; 1995.
41. Finlay, G. J.; Baguley, B. C; Wilson, W. R. A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially grow-ing carcinoma cells. Anal. Biochem. 139:272-277; 1984.
42. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anlicancer-drug screening. J. Nail. Cancer Inst. 82:1107-1112; 1990.
43. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55-63; 1983.
44. Finlay, G. J.; Wilson, W. R.; Baguley, B. C. Comparison of in vitro activity of cytotoxic drugs toward human carcinoma and leukaemia cell lines. Eur. J. Cancer Clin. Oncol. 22:655-662; 1986.
45. Scudiero, D. A.; Shoemaker, R. H.; Paull, K. D.; Monks, A.; Tierney, S.; Nofziger, T. H.; Currens, M. J.; Seniff, D.; Boyd, M. R. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumour cell lines. Cancer Res. 48:4827-4833; 1988.
46. Wilson, J. K.; Sargent, J. M.; Elgie, A. W.; Hill, J. G.; Taylor, C. G. A feasibility study of the MTT assay for chemosensitivity testing in ovarian malignancy. Br. J. Cancer 62:189-194; 1990.
47. Tanigawa, N.; Kern, D. H.; Hikasa, Y.; Morion, D. L. Rapid assay for evaluating the chemosensitivity of human tumors in soft agar culture. Cancer Res. 42:2159-2164; 1982.
48. Taetle, R.; Honeysett, J. M.; Rosen, F.; Shoemaker, R. Use of nude of mouse xenografts as preclinical drug screens. Further studies on m vitro growth of xenograft tumour colony-forming cells. Cancer 58:1969-1978; 1986.
49. Khoo, S. K.; Hurst, T.; Webb, M. J.; Dickie, G.; Kearsley, J.; Parsons, P. G.; Mackay, E. V. Cisplatin chemotherapy of ovarian cancer: Is short-term in vitro chemosensitivity predictive of longterm patient survival? Aust. N. Z. J. Obstet. Gynaecol. 28:313-317; 1988.
50. Jung, H. W.; Berens, M. E.; Krouwer, H. G.; Rosenblum, M. L. A three-dimensional micro-organ culture system optimized for in vitro growth of human malignant brain tumors. Neurosurgery 29: 390-398; 1991.
51. Baguley, B. C.; Marshall, E. S.; Whiltaker, J. R.; Dotchin, M. C; Nixon, J.; McCrystal, M. R.; Finlay, G. J.; Matthews, J. H. L.; Holdaway, K. M.; van Zijl, P. Resistance mechanisms determining the in vitro sensitivity to paclitaxcl of tumour cells cultured from patients with ovarian cancer. Eur. J. Cancer 3IA:230-237; 1995.
52. Barfod, I. H.; Barfod, N. M. Cell-production rates estimated by the use of vincristine sulphate and flow cytometry. I. An in vitro study using murine tumour cell lines. Cell Tissue Kinet. 13:1-8; 1980.
53. Hlatky, L.; Olesiak, M.; Hahnfeldt, P. Measurement of potential doubling time for human tumor xenografts using the cytokinesisblock method. Cancer Res. 56:1660-1663; 1996.
54. Rowinsky, E. K.; Donehower, R. C. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol. Ther. 52:35-84; 1991.
55. Khan, S. H.; Wahl, G. M. p53 and pRb prevent rereplication in response to microtubule inhibitors by mediating a reversible Gl arrest. Cancer Res. 58:396-401; 1998.
56. Jordan, M. A.; Wendeil, K.; Gardiner, S.; Deny, W. B.; Copp, H.; Wilson, L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res. 56:816-825; 1996.
57. Pardee, A. B. Gl events and regulation of cell proliferation. Science 246:603-608; 1989.
58. Cross, F.; Roberts, J.; Weintraub, H. Simple and complex cell cycles. Annu. Rev. Cell Biol. 5:341-395; 1989.
59. Smith, J. A.; Martin, L. Do cells cycle? Proc. Natl. Acad. Sci. USA 70:1263-1267; 1973.
60. Rewcastle, G. W.; Denny, W. A.; Bridges, A. J.; Zhou, H. R.; Cody, D. R.; McMichael, A.; Fry, D. \V. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-((phenylmethyl)amino)- and 4-(phenyIamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. J. Med. Chem. 38:3482-3487; 1995.
61. Bridges, A. J.; Zhou, H.; Cody, D. R.; Rewcastle, G. W.; McMichael, A.; Showalter, H. D.; Fry, D. W.; Kraker, A. J.; Denny, W. A. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimelhoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J. Med. Chem. 39:267-276; 1996.
62. Lane, D. P. Cancer-a death in the life of p53. Nature 362:786-787; 1993.
63. Polyak, K.; Xia, Y.; Zweier, J. L.; Kinzler, K. W.; Vogelstein, B. A model for p53-induced apoptosis. Nature 389:300-305; 1997.
64. Eastman, A. Activation of programmed cell death by anticancer agents: Cisplatin as a model system. Cancer Cells 2:275-280; 1990.
65. Perego, P.; Giarola, M.; Righelti, S. C; Supino, R.; Caserini, C; Delia, D.; Pierotti, M. A.; Miyashita, T.; Reed, J. C.; Zunino, F. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res. 56:556-562; 1996.
66. Fulda, S.; Los, M.; Friesen, C.; Debatin, K. M. Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. Int. J. Cancer 76:105-114; 1998.
67. Lees-Miller, S. P.; Sakaguchi, K.; Ullrich, S. J.; Appella, E.; Anderson, C. W. Human DNA-activated protein kinase phosphorylates serine-15 and serine-37 in the amino-terminal transactivation domain of human p53. Mol. Cell Biol. 12:5041-5049; 1992.
68. Woo, R. A.; McLure, K. G.; Leesmiller, S. P.; Rancourt, D. E.; Lee, P. \V. K. DNA-dependent protein kinase acts upstream of p53 in response to DNA damage. Nature 394:700-704; 1998.
69. Kastan, M. B.; Onyekwere, O.; Sidransky, D.; Vogelstein, B.; Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:6304-6311; 1991.
70. Vogelstein, B.; Kinzler, K. W. p53 function and dysfunction. Cell 70:523-526; 1992.
71. Sheikh, M. S.; Burns, T. F.; Huang, Y.; Wu, G. S.; Amundson, S.; Brooks, K. S.; Fornace, A. J.; Eldeiry, W. S. P53-dependcnt and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor o. Cancer Res. 58:1593-1598; 1998.
72. Thornberry, N. A.; Lazebnik, Y. Caspases: Enemies within. Science 281:1312-1316; 1998.
73. El-Deiry, W. S.; Harper, J. W.; O'Connor, P. M.; Velculescu, V. E.; Canman, C. E.; Jackman, J.; Pietenpol, J. A.; Burrell, M.; Hill, D. E.; Wang, Y. S.; Wiman, K. G.; Mercer, W. E.; Kastan, M. B.; Kohn, K. W.; Elledge, S. J.; Kinzler, K. W.; Vogelstein, B. Wafl/ cipl is induced in p53-mediated Gl arrest and apoptosis. Cancer Res. 54:1169-1174; 1994.
74. Bunz, F.; Dutriaux, A.; Waldman, T.; Zhou, S.; Brown, J. P.; Sedivy, J. M.; Kinzler, K. W.; Vogelstein, B. Requirement of p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497-1501; 1998.
75. Linke, S. P.; Clarkin, K. C.; Dileonardo, A.; Tsou, A.; Wahl, G. M. A reversible, p53-dependent GJGi cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev. 10:934-947; 1996.
76. Sugrue, M. M.; Shin, D. Y.; Lee, S. W.; Aaronson, S. A. Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53. Proc. Natl. Acad. Sci. USA 94:9648-9653; 1997.
77. Poon, R. Y. C.; Chau, M. S.; Yamashita, K.; Hunter, T. The role of Cdc2 feedback loop control in the DNA damage checkpoint in mammalian cells. Cancer Res. 57:5168-5178; 1997.
78. Strausfeld, U.; Labbe, J. C.; Fesquet, D.; Cavadore, J. C.; Picard, A.; Sadhu, K.; Russell, P.; Dorée, M. Dephosphorylation and activation of a p34cdc2 cyclin-B complex in vitro by human cdc25 protein. Nature 351:242-245; 1991.
79. Lopez-Girona, A.; Furnari, B.; Mondesert, O.; Russell, P. Nuclear localization of Cdc25 is regulated by DNA damage and a 14-3-3 protein. Nature 397:172-175; 1999.
80. Lock, R. B.; Stribinskiene, L. Dual modes of death induced by etoposide in human epithelial tumor cells allow bcl-2 to inhibit apoptosis without affecting clonogenic survival. Cancer Res. 56: 4006-4012; 1996.
81. Chaney, S. G.; Sancar, A. DNA repair-enzymatic mechanisms and relevance to drug response. J. Natl. Cancer. Inst. 88:1346-1360; 1996.
82. Weisenthal, L. M.; Marsden, J. A.; Dill, P. L.; Macaluso, C. K. A novel dye exclusion method for testing in vitro Chemosensitivity of human tumors. Cancer Res. 43:749-757; 1983.
83. Weisenthal, L. M.; Kern, D. H. Prediction of drug resistance in cancer chemotherapy: The Kem and DISC assays. Oncology 5: 93-1118; 1991.
84. Hinkley, H. J.; Bosanquet, A. G. The in vitro radiosensitivity of lymphocytes from chronic lymphocytic leukaemia using the dif-ferential staining cytotoxicity (DiSC) assay. II. Results on 40 patients. Int. J. Radiât. Biol. 61:111-121; 1992.
85. Sevin, B. U.; Peng, Z. L.; Perras, J. P.; Ganjei, P.; Penalver, M.; Averette, H. E. Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing. Gynecol. Oncol. 31:191-204; 1988.
86. Meitner, P. A. The fluorescent cytoprint assay: A new approach to in vitro chemosensitivity testing. Oncology 5:75-81; 1991.
87. Darzynkiewicz, Z.; Juan, G.; Li, X.; Gorczyca, W.; Murakami, T.; Traganos, F. Cytometry in cell necrobiology-analysis of apoptosis and accidental cell death (necrosis). Cytometry 27:1-20; 1997.
88. Wilbur, D. W.; Camacho, E. S.; Milliard, D. A.; Dill, P. L.; Weisenthal, L. M. Chemotherapy of non-small cell lung carcinoma guided by an in vitro drug resistance assay measuring total tumour cell kill. Br. J. Cancer 65:27-32; 1992.
89. Gorczyca, W.; Gong, J. P.; Darzynkiewicz, Z. Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res. 53:1945-1951; 1993.
90. Kitada, S.; Krajewski, S.; Miyashita, T.; Krajewska, M.; Rccd, J. C. Gamma-radiation induces uprcgulation of bax protein and apoptosis in radiosensitive cells m vivo. Oncogene 12:187-192; 1996.
91. Koopman, G.; Reutelingsperger, C. P.; Kuijten, G. A.; Rechnen, R. M.; Pals, S. T.; van-Ocrs, M. H. Annexin V for flow cytomelric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84:1415-1420; 1994.
92. Stanton, P. D.; Cooke, T. G.; Forster, G.; Smith, D.; Going, J. J. Cell kinetics in vivo of human breast cancer. Br. J. Surg. 83:98-102; 1996.
93. Marshall, E. S.; Holdaway, K. M.; Shaw, J. H. R; Finlay, G. J.; Matthews, J. H. L.; Baguley, B. C. Anticancer drug sensitivity profiles of new and established melanoma cell lines. Oncol. Res. 5:301-309; 1993.
94. Finlay, G. J.; Marshall, E. S.; Matthews, J. H. L.; Paull, K. D.; Baguley, B. C. In vitro assessment of N-(2-(dimcthylamino)ethyl)acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance. Cancer Chemothcr. Pharmacol. 31:401-406; 1993.